Insights
We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.
-
Patient Support Services Modeling, Made Actionable
A data-driven approach to patient support services modeling that helps manufacturers forecast demand, evaluate program design, and manage affordability, access, and cost with confidence.
-
Where Ecosystem Mapping Becomes Strategy
Market access ecosystem mapping helps biopharma teams move from identifying stakeholders to understanding how influence operates across the access landscape, enabling more coordinated engagement, stronger alignment, and more informed decision-making.
-
Prescription Drug Spending and the U.S. Health Spending Gap Compared with OECD Countries
Prescription drugs represent only a small portion of the overall difference in health care spending between the United States and comparable OECD countries. In 2021, prescription drug spending accounted for approximately $550, or 9.7%, of the $5,683 per capita spending gap, while inpatient and outpatient services accounted for nearly 80% of the difference. Administrative costs represented about 12% of the gap, highlighting the significant role of system complexity and operational overhead in driving higher U.S. health care spending.
-
When Lower Prices Don’t Mean Lower Costs: How Part D Benefit Changes Are Shifting Out-of-Pocket Spending in 2026 Under the Inflation Reduction Act
The 2026 Medicare Part D redesign lowers some drug prices but shifts cost sharing. Coinsurance and higher deductibles may increase out-of-pocket costs for many beneficiaries.
-
Designing for Coverage, Not Just Approval
Regulatory approval does not guarantee payer coverage. As reimbursement decisions increasingly depend on comparative value, budget impact, and real-world evidence, integrating HEOR and payer considerations into clinical trial design can help biopharma teams anticipate access challenges and support stronger reimbursement discussions at launch.
-
Market Access as a Driver of Biotech Value in 2026
Market access is increasingly shaping biopharma decisions earlier in the lifecycle. This article explores how policy uncertainty, evidence expectations, and access strategy are influencing development, investment, and long-term value realization.
-
Barriers to CAR-T Access in Medicare
Magnolia Market Access examines the factors shaping access to chimeric antigen receptor T-cell (CAR-T) therapies in the Medicare fee-for-service population.
-
PBM Reform in the Commercial Insurance Market: Understanding the Federal Budgetary Impact
Congress is considering changes that would significantly alter how Pharmacy Benefit Managers (PBMs) are compensated in commercial insurance. See our report and full analysis.
-
Case Study: Educating on Combination Product Access
How a biotech company equipped HCPs to navigate acquisition, coding, and coverage for a dual-therapy regimen.
-
Case Study: Launch Planning and Readiness
How program management and strategic alignment prepared a biopharma company for NDA submission and launch.
-
Case Study: Reimbursement & Market Access — Supporting Products with Required Imaging
How a manufacturer integrated imaging requirements into its access and patient support strategy.
-
Case Study: Leveraging Payer Insights to Shape Market Access Strategies and Tactics
How payer research helped refine value messaging, pricing strategy, and evidence plans.